[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 18, Issue 1 (Spring 2021) ::
Sci J Iran Blood Transfus Organ 2021, 18(1): 1-8 Back to browse issues page
Changes of miR-199a and miR-196b expression levels in blood donors suffering from asymptomatic hepatitis C
M. Mohammadpour, Z. Sharifi Dr., A. Arabkhazaeli Dr., F. Ghasemi Dr.
Keywords: Key words: Hepatitis C, Blood Donors, MicroRNAs
Full-Text [PDF 498 kb]   (198 Downloads)     |   Abstract (HTML)  (523 Views)
Type of Study: Research | Subject: Virology
Published: 2021/02/28
Full-Text:   (118 Views)
  1. Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses 2019; 11(1): 30.
  2. Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med 2017; 5(1): 8-17.
  3. von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, et al. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist 2019; 12: 947-55.
  4. Gao J, Ju C. Research progress on the direct antiviral drugs for hepatitis C virus. Biosci Trends 2017; 11(1): 41-5.
  5. Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol 2015; 21(42): 11984-2002.
  6. WHO. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c [27 July 2020].
  7. Teimoori A, Ebrahimi S, Keshtkar N, Khaghani S, Salmanzadeh S, Ghafari S. Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran. BMC Infect Dis 2019; 19(1): 389.
  8. Kermani FR, Hosseini KM, Kafi-Abad SA, Mansournia MA, Sharifi Z, Maghsudlu M. Hepatitis C (HCV) Viremic Rate and its Correlation to Demographic Factors among HCV Confirmed Iranian Blood Donors. Arch Iran Med 2019; 22(2): 76-9.
  9. Kałużna EM. MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection? Rev Med Virol 2014; 24(3): 169-85.
  10. Yuan H-L, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther 2018; 11: 3891-3900.
  11. Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, Kamel RR. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene 2016; 575(1): 66-70.
  12. El-Hefny M, Fouad S, Hussein T, Abdel-Hameed R, Effat H, Mohamed H, et al. Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. J Med Virol 2019; 91(1): 93-101.
  13. Li H, Jiang JD, Peng ZG. MicroRNA-mediated interactions between host and hepatitis C virus. World J Gastroenterol 2016; 22(4): 1487-96.
  14. Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatol Res 2017; 47(1): 60-9.
  15. Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: role in hepatitis C virus pathogenesis. Genes Dis 2015; 2(1): 35-45.
  16. Liu B, Xiang Y, Zhang HS. Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C. Mol Med Rep 2015; 12(1): 105-10.
  17. El-Guendy NM, Helwa R, El-Halawany MS, Ali SAR, Aly MT, Alieldin NH, et al. The liver MicroRNA expression profiles associated with chronic hepatitis C virus (HCV) genotype-4 infection: a preliminary study. Hepat Mon 2016; 16(4): e33881.
  18. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51(5): 1494-504.
  19. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50(3): 453-60.
  20. El-Ahwany EG, Mourad L, Zoheiry MM, Abu-Taleb H, Hassan M, Atta R, et al. MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. Arch Med Sci 2019; 15(6): 1454-61.
  21. Chang CC, Lin CC, Hsieh WL, Lai HW, Tsai CH,
    Cheng YW. MicroRNA expression profiling in PBMCs: a potential diagnostic biomarker of chronic hepatitis C. Dis Markers 2014; 2014: 367157.
  22. Ranjbar Kermani F, Amini Kafi Abad S, Mousavi Hosseini K, Maghsudlu M, Sharifi Z. Update on HCV genotypes among Iranian blood donors. Sci J Iran Blood Transfus Organ 2020; 17(1): 1-12. [Article in Farsi]
  23. Grek M, Piekarska A, Bartkowiak J, Fendler W, Kuydowicz J, Wroblewski P, et al. Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. Int J Mol Med 2011; 28(5): 875-80.
  24. Scagnolari C, Zingariello P, Vecchiet J, Selvaggi C, Racciatti D, Taliani G, et al. Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J 2010; 7(1): 311.


Sci J Iran Blood Transfus Organ 2021;18 (1):1-8
Original Article

Changes of miR-199a and miR-196b expression levels in blood donors suffering from asymptomatic hepatitis C
Mohammadpour M.1, Sharifi Z.1, Arabkhazaeli A.1, Ghasemi F.1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Background and Objectives
Hepatitis C virus is the main cause of hepatitis C infection that usually has no symptoms at early stages. Studies have shown changes in the expression level of microRNAs in various diseases such as hepatitis. MiR-199a and miR-196b have an inhibitory effect on hepatitis C virus. In a recent study, we examined the expression levels of miR-199a and miR-196b in serum samples of asymptomatic hepatitis C infected blood donors in comparison to serum samples of healthy blood donors; based on the results, the importance of microRNAs in different stages of hepatitis C infection was evaluated.
Materials and Methods
In this case control study, first total RNA extraction from 106 serum samples of healthy blood donors (control group) and 106 serum samples of asymptomatic hepatitis C infected blood donors (case group) was carried out. After cDNA synthesis, the expression level of miR-199a and miR-196b were evaluated by SYBR Green real-time PCR, and the results were analyzed by REST 2009 software.
Expression level of miR-196b in the case group compared to the control group was lower (p  0.001). No statistically significant difference was observed in the expression level of miR-199a between the two groups.
With regard to lower expression level of miR-196b, and given no significant difference of miR-199a expression level in the case group in comparison to the control group, future studies on the role of miR-196b in this disease are required.
Key words: Hepatitis C, Blood Donors, MicroRNAs
Received:  19 Jul  2020
Accepted: 17 Nov 2020

Correspondence: Ghasemi F., PhD of Medical Biotechnology. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.          
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052230; Fax: (+9821) 88601554
E-mail: Ghasemi_808@yahoo.com
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadpour M, Sharifi Z, Arabkhazaeli A, Ghasemi F. Changes of miR-199a and miR-196b expression levels in blood donors suffering from asymptomatic hepatitis C. Sci J Iran Blood Transfus Organ. 2021; 18 (1) :1-8
URL: http://bloodjournal.ir/article-1-1366-en.html

Volume 18, Issue 1 (Spring 2021) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 4313